Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV : A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial
Long-acting (LA) injectable antiretroviral therapy (ART) was found noninferior to daily oral ART in Phase 3 trials with high patient satisfaction. Limited information on provider experiences with LA ART exists, which is critical to inform real-world implementation. An online survey of health providers from the 13 countries participating in the Phase 3b ATLAS-2M trial was conducted. A total of 293 providers responded to questions on LA ART feasibility. Multivariable regression was utilized to identify factors related to the feasibility of LA ART every month and every 2 months within routine care such as the characteristics, experiences, and attitudes of providers, and perceptions of patient benefits and barriers. A majority of providers indicated that it would be very feasible (62.8%) or somewhat feasible (32.1%) to administer monthly LA ART. Feasibility scores were higher for delivering LA ART every 2 months versus monthly (mean 28.3 vs. 26.9; p value <.001). African providers had higher odds of perceived overall feasibility of monthly LA ART [adjusted odds ratio (aOR) 2.9, 95% confidence interval (CI) 1.9-4.4] versus those from other regions, as did providers reporting a greater number of benefits for patients (aOR 1.1, 95% CI 1.0-1.1) versus those reporting less. Providers reporting a greater number of patient barriers to adhere to clinic appointments had lower odds of perceived feasibility of monthly LA ART (aOR 0.8, 95% CI 0.7-1.0) versus those reporting less. Findings highlight the need for further implementation research regarding barriers, facilitators, and strategies to optimize the introduction of LA ART outside of clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
AIDS research and human retroviruses - 37(2021), 3 vom: 09. März, Seite 207-213 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kerrigan, Deanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase III |
|---|
| Anmerkungen: |
Date Completed 18.08.2021 Date Revised 18.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/AID.2020.0208 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318881667 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318881667 | ||
| 003 | DE-627 | ||
| 005 | 20231225170302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/AID.2020.0208 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318881667 | ||
| 035 | |a (NLM)33323029 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kerrigan, Deanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV |b A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2021 | ||
| 500 | |a Date Revised 18.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Long-acting (LA) injectable antiretroviral therapy (ART) was found noninferior to daily oral ART in Phase 3 trials with high patient satisfaction. Limited information on provider experiences with LA ART exists, which is critical to inform real-world implementation. An online survey of health providers from the 13 countries participating in the Phase 3b ATLAS-2M trial was conducted. A total of 293 providers responded to questions on LA ART feasibility. Multivariable regression was utilized to identify factors related to the feasibility of LA ART every month and every 2 months within routine care such as the characteristics, experiences, and attitudes of providers, and perceptions of patient benefits and barriers. A majority of providers indicated that it would be very feasible (62.8%) or somewhat feasible (32.1%) to administer monthly LA ART. Feasibility scores were higher for delivering LA ART every 2 months versus monthly (mean 28.3 vs. 26.9; p value <.001). African providers had higher odds of perceived overall feasibility of monthly LA ART [adjusted odds ratio (aOR) 2.9, 95% confidence interval (CI) 1.9-4.4] versus those from other regions, as did providers reporting a greater number of benefits for patients (aOR 1.1, 95% CI 1.0-1.1) versus those reporting less. Providers reporting a greater number of patient barriers to adhere to clinic appointments had lower odds of perceived feasibility of monthly LA ART (aOR 0.8, 95% CI 0.7-1.0) versus those reporting less. Findings highlight the need for further implementation research regarding barriers, facilitators, and strategies to optimize the introduction of LA ART outside of clinical trials | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a feasibility | |
| 650 | 4 | |a implementation | |
| 650 | 4 | |a injectable | |
| 650 | 4 | |a long-acting injectable ART | |
| 650 | 4 | |a providers | |
| 700 | 1 | |a Murray, Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez Karver, Tahilin |e verfasserin |4 aut | |
| 700 | 1 | |a Mantsios, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Walters, Nicki |e verfasserin |4 aut | |
| 700 | 1 | |a Hudson, Krischan |e verfasserin |4 aut | |
| 700 | 1 | |a Kaplan-Lewis, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Pulido, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Bassa, Ayesha Cassim |e verfasserin |4 aut | |
| 700 | 1 | |a Margolis, David |e verfasserin |4 aut | |
| 700 | 1 | |a Galai, Noya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS research and human retroviruses |d 1990 |g 37(2021), 3 vom: 09. März, Seite 207-213 |w (DE-627)NLM012611727 |x 1931-8405 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2021 |g number:3 |g day:09 |g month:03 |g pages:207-213 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/AID.2020.0208 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2021 |e 3 |b 09 |c 03 |h 207-213 | ||